Drug Profile
Research programme: plasminogen activator inhibitor 1 monoclonal antibodies - AstraZeneca
Alternative Names: anti-PAI-1 MAb - AstraZenecaLatest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Monoclonal antibodies
- Mechanism of Action Plasminogen activator inhibitor-1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Gastrointestinal disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in United Kingdom (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in United Kingdom (Parenteral)